Literature DB >> 14680447

Verteporfin ocular photodynamic therapy.

Sophie J Bakri1, Peter K Kaiser.   

Abstract

This article reviews the pharmacotherapeutics of verteporfin (Visudyne), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials with verteporfin to treat subfoveal choroidal neovascularisation in age-related macular degeneration, ocular histoplasmosis syndrome and pathologic myopia. In addition, the safety profile and side effects of verteporfin are discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14680447     DOI： 10.1517/14656566.5.1.195

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

2.  Photodynamic inactivation of Bacillus spores, mediated by phenothiazinium dyes.

Authors:  Tatiana N Demidova; Michael R Hamblin
Journal:  Appl Environ Microbiol       Date:  2005-11       Impact factor: 4.792

3.  Abnormal Expression of YAP Is Associated With Proliferation, Differentiation, Neutrophil Infiltration, and Adverse Outcome in Patients With Nasal Inverted Papilloma.

Authors:  Tian Yuan; Rui Zheng; Xiang-Min Zhou; Peng Jin; Zhi-Qun Huang; Xiao-Xue Zi; Qing-Wu Wu; Wei-Hao Wang; Hui-Yi Deng; Wei-Feng Kong; Hui-Jun Qiu; Sui-Zi Zhou; Qian-Min Chen; Yan-Yi Tu; Tao Li; Jing Liu; Kai Sen Tan; Hsiao Hui Ong; Li Shi; Zhuang-Gui Chen; Xue-Kun Huang; Qin-Tai Yang; De-Yun Wang
Journal:  Front Cell Dev Biol       Date:  2021-04-15

4.  Phototriggerable liposomes: current research and future perspectives.

Authors:  Anu Puri
Journal:  Pharmaceutics       Date:  2013-12-19       Impact factor: 6.321

Review 5.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.

Authors:  Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2019-09-06       Impact factor: 6.321

Review 6.  The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.

Authors:  Changran Wei; Xiangqi Li
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.